'Bionanotechnology from Theory to Practice' is a short online, course providing an interdisciplinary and up-to-date overview of the rapidly developing area of bionanotechnology
Page URL: https://www.bionews.org.uk/page_151573

Mitochondrial antioxidant may prevent future heart disease

24 August 2020
Appeared in BioNews 1061

An antioxidant treatment during pregnancy may prevent heart problems caused by low oxygen levels.

Chronic fetal hypoxia – low oxygen levels in the womb – is one of the most common pregnancy complications and can be diagnosed by a routine scan. Affected babies can experience heart problems later in life, but researchers from the University of Cambridge have reported that administering a specialised mitochondrial antioxidant to the mother may prevent or reduce these harmful effects.

'Many people may be predisposed to heart disease as adults because of the low level of oxygen they received in the womb. By providing a specific mitochondria-targeted antioxidant supplement to mothers whose pregnancy is complicated by fetal hypoxia, we can potentially prevent this,' said senior author Professor Dino Giussani.

Oxygen deprivation leads to a state of 'oxidative stress' in the mitochondria of the fetal cells. Mitochondria are structures inside cells and are where energy is generated using sugars and oxygen brought to the cell by the bloodstream. Oxidative stress in fetuses can cause damage to the heart and blood vessels that increases the risk of cardiovascular disease in adulthood. 

The researchers used an antioxidant to reduces oxidative stress and prevent downstream complications. They chose MitoQ because it is known to be able to cross the membrane into the mitochondria and to accumulate there.

To test if MitoQ would successfully cross the placenta the researchers administered MitoQ to pregnant sheep under low oxygen conditions, and reported that this reduced the risk of high blood pressure and consequent heart diseases in the offspring.

Chicken embryos were also used to characterise the role of MitoQ therapy on the embryonic heart independent of any influence from the mother or the placenta. 

Professor James Leiper, associate medical director at the British Heart Foundation who was not involved in the study, said 'Further research is now needed to translate these findings from animals to humans and identify the most effective time in development to give the MitoQ supplement to 'at risk' babies - whether that's a particular point during pregnancy or soon after birth. Overcoming this next hurdle will enable it to be tested in clinical trials.'

The research was published in Science Advances.

Prevention of heart disease can start before birth
University of Cambridge |  19 August 2020
Translatable mitochondria-targeted protection against programmed cardiovascular dysfunction
Science Advances |  19 August 2020
16 November 2020 - by Blair Sowry 
A gene linked to heart development in the embryo also has a role in human immune system function, new research has found...
2 December 2019 - by Dr Rosie Morley 
Stem cell therapies may become redundant in repairing cardiac function after a heart attack, suggests a new study in mice...
1 April 2019 - by Dr Helen Robertson 
Exposure to low levels of oxygen in the womb may cause fertility problems for female offspring later in life...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.